ClinicalTrials.gg
TerminatedNCT04583423Updated Jul 17, 2025Results posted

A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)

A Phase 2 interventional study of MK-3655 and Placebo in Nonalcoholic Steatohepatitis, sponsored by Merck Sharp & Dohme LLC. Terminated at 180 sites in 24 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Business reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
183
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Merck & Co., Inc.

Enrollment
2nd of 10
183 · median 113
Started
2020
with 1 other
Phase 2
7 of 11
none open now
Registered
4th of 11
by date

Among the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2020, is one of 7 in phase 2, and was the 4th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

None of the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc as a file.
02

Study summary

This study will evaluate the effect of each dose of MK-3655 versus placebo on the percentage of individuals with NASH resolution without worsening of fibrosis after 52 weeks. The primary hypothesis of the study is that at least 1 dose of MK-3655 is superior to placebo with respect to the percentage of individuals with NASH resolution without worsening of fibrosis after 52 weeks.

03

Conditions studied

  • Nonalcoholic Steatohepatitis

Keywords

  • Non-alcoholic fatty liver disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has histological confirmation of NASH
  • Is a male or female aged 18 years to 80 years (in Japan and Taiwan aged 20 to 80 years)
  • Has a (BMI) ≥25 kg/m\^2 and ≤50 kg/m\^2 and stable weight for the past 3 months
  • Has no history of Type 2 diabetes mellitus (T2DM) OR a history of T2DM controlled by diet or stable doses of antihyperglycemic agents (AHAs)
  • use by male participants should be consistent with local regulations.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and she is not a woman of (WOCBP) OR she is a WOCBP and uses a contraceptive method that is highly effective during the intervention period and for at least 16 weeks after the last dose of study intervention.

Exclusion criteria

Exclusion Criteria

  • Has presence of cirrhosis on liver
  • Has Type 1 diabetes
  • Has a history of , unless cancer free ≥5 years, or is under evaluation for active or suspected malignancy except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
  • Has a history of bariatric surgery ≤5 years before study participation
  • Has undergone a major surgical procedure ≤3 months before study participation or has major surgery planned during the study
  • Has a history or evidence of chronic liver disease other than NASH. Individuals with a history of or C may be eligible for participation.
  • Has significant systemic or major illnesses other than liver disease, including recent events (≤6 months before study entry) of congestive heart failure, unstable coronary artery disease, arterial revascularization, pulmonary disease, renal failure, stroke, , or organ transplantation
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
183 participants (actual)

Study arms

  • Experimental
    MK-3655 50 mg

    Following a 2-week placebo run-in, participants will receive MK-3655 50 mg by subcutaneous (SC) injection once every 4 weeks (Q4W) for 52 weeks.

    Drug: MK-3655

  • Experimental
    MK-3655 100 mg

    Following a 2-week placebo run-in, participants will receive MK-3655 100 mg by SC injection Q4W for 52 weeks.

    Drug: MK-3655

  • Experimental
    MK-3655 300 mg

    Following a 2-week placebo run-in, participants will receive MK-3655 300 mg by SC injection Q4W for 52 weeks.

    Drug: MK-3655

  • Placebo comparator
    Placebo

    Following a 2-week placebo run-in, participants will receive Placebo by SC injection Q4W for 52 weeks.

    Drug: Placebo

Interventions

  • DrugMK-3655

    MK-3655 50, 100 or 300 dose for injection

    Also known as: NGM313

  • DrugPlacebo

    Matching placebo to MK-3655

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis After 52 Weeks

    The NASH Clinical Research Network (CRN) scoring system evaluated by Blinded Independent Central Review (BICR) was used to assess treatment response. The NASH CRN scoring scales were: lobular inflammation score (0-3); hepatocyte ballooning score (0-2); steatosis score (0-3); and fibrosis score (0-4). NASH resolution was defined as a score of 0-1 for inflammation, 0 for ballooning, and any grade of steatosis.

    Time frame: Week 52

  2. Percentage of Participants Who Experienced an Adverse Event (AE)

    An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study.

    Time frame: Up to 64 weeks

  3. Percentage of Participants Discontinuing Study Medication Due to an AE

    An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study.

    Time frame: Up to 52 weeks

Secondary outcomes

  1. Mean Percent Relative Reduction From Baseline in Liver Fat Content (LFC) After 24 Weeks

    LFC % was measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF) and evaluated by BICR. MRI-PDFF is a highly accurate noninvasive measure of the proportion of fat content of a tissue.

    Time frame: Baseline and Week 24

  2. Percentage of Participants With ≥1 Stage Improvement in Fibrosis Without Worsening of Steatohepatitis Assessed With the NASH CRN Scoring System After 52 Weeks

    Participants were evaluated with the NASH CRN scoring system with BICR with ≥1 stage improvement in fibrosis without worsening of steatohepatitis defined as no increase in the ballooning, inflammation, or steatosis scores.

    Time frame: Week 52

  3. Percentage of Participants With ≥2 Point Improvement in NAS With ≥1 Point Improvement in Inflammation or Ballooning Without Worsening of Fbrosis by Histology (Evaluated by BICR) After 52 Weeks

    Participants with ≥2 point improvement in the NAS with ≥1 point improvement in inflammation or ballooning without worsening of fibrosis were assessed with the NASH CRN scoring system (evaluated by BICR). The NAS was calculated as the unweighted sum of the scores and ranges from 0-8 (highest activity).

    Time frame: Week 52

07

Results

Posted Apr 29, 2024

Participant flow

Males and females with pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) aged 18 to 80 years (in Japan and Taiwan, aged 20 to 80 years were randomized in this study

Participant flow — Overall Study
MilestoneMK-3655 50 mgMK-3655 100 mgMK-3655 300 mgPlacebo
Started45484644
Received 1st dose45474644
Completed101188
Not completed35373836
Withdrew: Lost to follow-up0102
Withdrew: Study terminated by sponsor32353633
Withdrew: Withdrawal by subject3121

Outcome measures

PrimaryPercentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis After 52 Weeks

The NASH Clinical Research Network (CRN) scoring system evaluated by Blinded Independent Central Review (BICR) was used to assess treatment response. The NASH CRN scoring scales were: lobular inflammation score (0-3); hepatocyte ballooning score (0-2); steatosis score (0-3); and fibrosis score (0-4). NASH resolution was defined as a score of 0-1 for inflammation, 0 for ballooning, and any grade of steatosis.

Time frame:
Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis After 52 Weeks
Percentage of ParticipantsMK-3655 50 mgMK-3655 100 mgMK-3655 300 mgPlacebo
Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis After 52 Weeks16.714.317.65.9
Statistical analysis
  • MK-3655 50 mg vs Placebo · Miettinen and Nurminen's method · p = 0.3504 · Difference in percentages: 10.4 · 95% CI -13.4 to 35.1Difference=% 50-mg MK-3655 minus % placebo
  • MK-3655 100 mg vs Placebo · Miettinen and Nurminen's method · p = 0.3730 · Difference in percentages: 9.2 · 95% CI -15.6 to 32.1Difference=% 100-mg MK-3655 minus % placebo
  • MK-3655 300 mg vs Placebo · Miettinen and Nurminen's method · p = 0.1428 · Difference in percentages: 15.4 · 95% CI -8.5 to 42.3Difference=% 300-mg MK-3655 minus % placebo
PrimaryPercentage of Participants Who Experienced an Adverse Event (AE)

An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study.

Time frame:
Up to 64 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experienced an Adverse Event (AE)
Percentage of ParticipantsMK-3655 50 mgMK-3655 100 mgMK-3655 300 mgPlacebo
Percentage of Participants Who Experienced an Adverse Event (AE)73.370.276.177.3
PrimaryPercentage of Participants Discontinuing Study Medication Due to an AE

An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study.

Time frame:
Up to 52 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Discontinuing Study Medication Due to an AE
Percentage of ParticipantsMK-3655 50 mgMK-3655 100 mgMK-3655 300 mgPlacebo
Percentage of Participants Discontinuing Study Medication Due to an AE2.2000
SecondaryMean Percent Relative Reduction From Baseline in Liver Fat Content (LFC) After 24 Weeks

LFC % was measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF) and evaluated by BICR. MRI-PDFF is a highly accurate noninvasive measure of the proportion of fat content of a tissue.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent Change
Mean Percent Relative Reduction From Baseline in Liver Fat Content (LFC) After 24 Weeks
Percent ChangeMK-3655 50 mgMK-3655 100 mgMK-3655 300 mgPlacebo
Mean Percent Relative Reduction From Baseline in Liver Fat Content (LFC) After 24 Weeks30.1 (17.5 to 42.7)30.0 (18.2 to 41.8)37.2 (25.5 to 48.8)11.0 (-0.9 to 23.0)
Statistical analysis
  • MK-3655 50 mg vs Placebo · Difference in least square (ls) means: 19.1 · 95% CI 1.7 to 36.4Difference=LS Mean 50 mg minus LS Mean Placebo
  • MK-3655 100 mg vs Placebo · Difference in ls means: 19.0 · 95% CI 2.2 to 35.8Difference=LS Mean 100 mg minus LS Mean Placebo
  • MK-3655 300 mg vs Placebo · Difference in ls means: 26.1 · 95% CI 9.5 to 42.8Difference=LS Mean 300 mg minus LS Mean Placebo
SecondaryPercentage of Participants With ≥1 Stage Improvement in Fibrosis Without Worsening of Steatohepatitis Assessed With the NASH CRN Scoring System After 52 Weeks

Participants were evaluated with the NASH CRN scoring system with BICR with ≥1 stage improvement in fibrosis without worsening of steatohepatitis defined as no increase in the ballooning, inflammation, or steatosis scores.

Time frame:
Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥1 Stage Improvement in Fibrosis Without Worsening of Steatohepatitis Assessed With the NASH CRN Scoring System After 52 Weeks
Percentage of ParticipantsMK-3655 50 mgMK-3655 100 mgMK-3655 300 mgPlacebo
Percentage of Participants With ≥1 Stage Improvement in Fibrosis Without Worsening of Steatohepatitis Assessed With the NASH CRN Scoring System After 52 Weeks22.238.129.417.6
Statistical analysis
  • MK-3655 50 mg vs Placebo · Miettinen and Nurminen's method · p = 0.8978 · Difference in percentages: 1.6 · 95% CI -26.5 to 30.3Difference=% 50 mg minus % Placebo
  • MK-3655 100 mg vs Placebo · Miettinen and Nurminen's method · p = 0.1869 · Difference in parentages: 20.0 · 95% CI -10.6 to 46.4Difference=% 100 mg minus % Placebo
  • MK-3655 300 mg vs Placebo · Miettinen and Nurminen's method · p = 0.5636 · Difference in percentages: 8.5 · 95% CI -22.1 to 38.5Difference=% 300 mg minus % Placebo
SecondaryPercentage of Participants With ≥2 Point Improvement in NAS With ≥1 Point Improvement in Inflammation or Ballooning Without Worsening of Fbrosis by Histology (Evaluated by BICR) After 52 Weeks

Participants with ≥2 point improvement in the NAS with ≥1 point improvement in inflammation or ballooning without worsening of fibrosis were assessed with the NASH CRN scoring system (evaluated by BICR). The NAS was calculated as the unweighted sum of the scores and ranges from 0-8 (highest activity).

Time frame:
Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥2 Point Improvement in NAS With ≥1 Point Improvement in Inflammation or Ballooning Without Worsening of Fbrosis by Histology (Evaluated by BICR) After 52 Weeks
Percentage of ParticipantsMK-3655 50 mgMK-3655 100 mgMK-3655 300 mgPlacebo
Percentage of Participants With ≥2 Point Improvement in NAS With ≥1 Point Improvement in Inflammation or Ballooning Without Worsening of Fbrosis by Histology (Evaluated by BICR) After 52 Weeks33.347.635.329.4
Statistical analysis
  • MK-3655 50 mg vs Placebo · Miettinen and Nurminen's method · p = 0.9174 · Difference in percentages: 1.6 · 95% CI -28.6 to 32.6Difference=% 50 mg minus % Placebo
  • MK-3655 100 mg vs Placebo · Miettinen and Nurminen's method · p = 0.2720 · Difference in percentages: 18.5 · 95% CI -14.5 to 47.1Difference=% 100 mg minus % Placebo
  • MK-3655 300 mg vs Placebo · Miettinen and Nurminen's method · p = 0.7586 · Difference in percentages: 5.3 · 95% CI -26.7 to 37.3Difference= % 300 mg minus % Placebo

Adverse events

Collected over Up to 64 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MK-3655 50 mg0/45 (0%)1/45 (2.2%)19/45 (42.2%)
MK-3655 100 mg0/48 (0%)1/47 (2.1%)26/47 (55.3%)
MK-3655 300 mg0/46 (0%)1/46 (2.2%)27/46 (58.7%)
Placebo0/44 (0%)8/44 (18.2%)21/44 (47.7%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventMK-3655 50 mgMK-3655 100 mgMK-3655 300 mgPlacebo
Sinoatrial blockCardiac disorders0/450/470/461/44
CataractEye disorders0/450/470/461/44
Abdominal painGastrointestinal disorders0/450/470/461/44
Large intestine polypGastrointestinal disorders0/450/470/461/44
Rectal haemorrhageGastrointestinal disorders0/450/470/461/44
Non-cardiac chest painGeneral disorders0/450/470/461/44
Pyelonephritis acuteInfections and infestations0/450/470/461/44
Forearm fractureInjury, poisoning and procedural complications0/450/470/461/44
Acute kidney injuryRenal and urinary disorders0/450/470/461/44
NephrolithiasisRenal and urinary disorders0/450/470/461/44
Most frequent other events
Showing 10 of 16
Most frequent other events
EventMK-3655 50 mgMK-3655 100 mgMK-3655 300 mgPlacebo
COVID-19Infections and infestations4/459/475/465/44
ArthralgiaMusculoskeletal and connective tissue disorders1/451/477/461/44
DiarrhoeaGastrointestinal disorders4/457/475/463/44
HypertensionVascular disorders2/456/476/461/44
HeadacheNervous system disorders2/451/475/463/44
Increased appetiteMetabolism and nutrition disorders2/455/474/460/44
NauseaGastrointestinal disorders2/453/471/464/44
PyrexiaGeneral disorders2/452/472/464/44
Back painMusculoskeletal and connective tissue disorders1/453/474/463/44
NasopharyngitisInfections and infestations2/454/472/460/44

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MK-3655 50 mgMK-3655 100 mgMK-3655 300 mgPlaceboTotal
Mean59.6 ± 8.954.3 ± 12.356.6 ± 11.355.8 ± 10.156.5 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)MK-3655 50 mgMK-3655 100 mgMK-3655 300 mgPlaceboTotal
Female2520231987
Male2028232596
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MK-3655 50 mgMK-3655 100 mgMK-3655 300 mgPlaceboTotal
Hispanic or Latino1213171860
Not Hispanic or Latino33342825120
Unknown or Not Reported01113
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MK-3655 50 mgMK-3655 100 mgMK-3655 300 mgPlaceboTotal
American Indian or Alaska Native00011
Asian1518161665
Native Hawaiian or Other Pacific Islander10102
Black or African American32117
White26282726107
More than one race00101
Unknown or Not Reported00000
Baseline Fibrosis Stage
Baseline Fibrosis Stage(Participants)MK-3655 50 mgMK-3655 100 mgMK-3655 300 mgPlaceboTotal
Stage 22122212185
Stage 32426252398
Percent Liver Fat Content
Percent Liver Fat Content(Participants)MK-3655 50 mgMK-3655 100 mgMK-3655 300 mgPlaceboTotal
<20%30233031114
≥ 20%1525161369
Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes Mellitus (T2DM)(Participants)MK-3655 50 mgMK-3655 100 mgMK-3655 300 mgPlaceboTotal
Yes2225252496
No2323212087
Region
Region(Participants)MK-3655 50 mgMK-3655 100 mgMK-3655 300 mgPlaceboTotal
Japan1112111145
East Asia excluding Japan655521
Other28313028117
08

Study locations

180 sites
  • Adobe Clinical Research, LLC ( Site 2644)
    Tucson, Arizona 85712, United States
  • Arizona Liver Health ( Site 9026)
    Tucson, Arizona 85712, United States
  • Del Sol Research Management ( Site 2674)
    Tucson, Arizona 85715, United States
  • Arkansas Gastroenterology - North Little Rock ( Site 9015)
    North Little Rock, Arkansas 72117, United States
  • Hope Clinical Research, Inc. ( Site 2601)
    Canoga Park, California 91303, United States
  • Velocity Clinical Research, Huntington Park ( Site 9022)
    Huntington Park, California 90255, United States
  • UCSD - Altman Clinical and Translational Research Institute -UC San Diego NAFLD Research Center ( Si
    La Jolla, California 92037, United States
  • Ruane Clinical Research Group, Inc ( Site 9014)
    Los Angeles, California 90036, United States
  • Velocity Clinical Research, Westlake ( Site 9013)
    Los Angeles, California 90057, United States
  • Catalina Research Institute, LLC ( Site 2643)
    Montclair, California 91763, United States
  • Velocity Clinical Research, Panorama City ( Site 9001)
    Panorama City, California 91402, United States
  • California Liver Research Institute ( Site 9025)
    Pasadena, California 91105, United States
  • Quest Clinical Research ( Site 9011)
    San Francisco, California 94115, United States
  • Velocity Clinical Research, Santa Ana ( Site 9002)
    Santa Ana, California 92704, United States
  • Peak Gastroenterology Associates ( Site 2645)
    Colorado Springs, Colorado 80920, United States
  • Top Medical Research, Inc ( Site 2673)
    Cutler Bay, Florida 33189, United States
  • Covenant Metabolic Specialists, LLC ( Site 9027)
    Fort Myers, Florida 33912, United States
  • North Florida South Georgia Veterans Health System ( Site 2613)
    Gainesville, Florida 32608, United States
  • Indago Research and Health Center Inc ( Site 2610)
    Hialeah, Florida 33012, United States
  • Sweet Hope Research Specialty Inc ( Site 2660)
    Hialeah, Florida 33016, United States
  • Genoma Research Group, Inc. ( Site 2669)
    Miami, Florida 33173, United States
  • Floridian Clinical Research, LLC ( Site 2656)
    Miami Lakes, Florida 33016-1518, United States
  • Ocean Blue Medical Research Center Inc ( Site 2667)
    Miami Springs, Florida 33166, United States
  • Sensible Healthcare Llc ( Site 2607)
    Ocoee, Florida 34761, United States
  • Synexus Research ( Site 2672)
    Orlando, Florida 32806, United States
  • Southeast Clinical Research Center ( Site 9003)
    Dalton, Georgia 30720, United States
  • The University of Iowa ( Site 2655)
    Iowa City, Iowa 52242, United States
  • Legacy Clinical Solutions: Tandem Clinical Research, LLC ( Site 2650)
    Marrero, Louisiana 70072, United States
  • The National Diabetes & Obesity Research Institute ( Site 9017)
    Biloxi, Mississippi 39532, United States
  • Kansas City Research Institute ( Site 9018)
    Kansas City, Missouri 64131, United States
  • Excel Clinical Research, LLC ( Site 2603)
    Las Vegas, Nevada 89109, United States
  • Velocity Clinical Research, Syracuse ( Site 9016)
    East Syracuse, New York 13057, United States
  • NYU Langone Health, New York ( Site 2627)
    New York, New York 10016, United States
  • Hillmont G.I. ( Site 9019)
    Flourtown, Pennsylvania 19031, United States
  • Regional Gastroenterology Associates of Lancaster, LTD ( Site 9020)
    Lancaster, Pennsylvania 17601, United States
  • Regional Gastroenterology Associates of Lancaster, LTD ( Site 9004)
    Wyomissing, Pennsylvania 19610, United States
  • Premier Medical Group ( Site 9010)
    Clarksville, Tennessee 37040, United States
  • Texas Clinical Research Institute ( Site 2619)
    Arlington, Texas 76012, United States
  • The Liver Institute at Methodist Dallas Medical Center ( Site 2638)
    Dallas, Texas 75203, United States
  • DHR Health Institute for Research and Development ( Site 9006)
    Edinburg, Texas 78539, United States
  • South Texas Research Institute ( Site 9012)
    Edinburg, Texas 78539, United States
  • Baylor College of Medicine - Advanced Liver Therapies ( Site 2670)
    Houston, Texas 77030, United States
  • The Crofoot Research Center, Inc. ( Site 2611)
    Houston, Texas 77098, United States
  • Quality Research ( Site 9024)
    San Antonio, Texas 78209, United States
  • American Research Corporation at Texas Liver Institute ( Site 2634)
    San Antonio, Texas 78215, United States
  • Clinical Trials of Texas, LLC ( Site 2614)
    San Antonio, Texas 78229, United States
  • Impact Research Institute ( Site 2685)
    Waco, Texas 76710, United States
  • Virginia Commonwealth University Health System ( Site 2657)
    Richmond, Virginia 23298, United States
  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0010)
    Mar del Plata, Buenos Aires 7600, Argentina
  • Hospital Universitario Austral ( Site 0003)
    Pilar, Buenos Aires B1629AHJ, Argentina
  • DIM Clínica Privada ( Site 0011)
    Ramos Mejía, Buenos Aires 1704, Argentina
  • Hospital Británico de Buenos Aires ( Site 0002)
    Buenos Aires, Buenos Aires F.D. 1280, Argentina
  • Glenny Corp. S.A.-CLINICAL RESEARCH ( Site 0013)
    Buenos Aires, Buenos Aires F.D. C1430CKE, Argentina
  • Hospital Italiano de Buenos Aires-Hepatology ( Site 0014)
    Ciudad de Buenos Aires, Buenos Aires F.D. C1199ABB, Argentina
  • Hospital Provincial del Centenario ( Site 0007)
    Rosario, Santa Fe Province S2002KDS, Argentina
  • Hospital Aleman ( Site 0009)
    Buenos Aires, C1118AAT, Argentina
  • Clinica de nefrologia urologia y enfermedades cardiovasculares ( Site 0008)
    Santa Fe, S3000BPJ, Argentina
  • Royal Prince Alfred Hospital ( Site 0102)
    Camperdown, New South Wales 2050, Australia
  • St George Hospital ( Site 0104)
    Kogarah, New South Wales 2217, Australia
  • Flinders Medical Centre ( Site 0107)
    Bedford Park, South Australia 5042, Australia
  • GIRI GI Research Institute - Vancouver ( Site 0404)
    Vancouver, British Columbia V5Z 2K5, Canada
  • University Health Network - Toronto General Hospital ( Site 0401)
    Toronto, Ontario M5G 2C4, Canada
  • McGill University Health Centre ( Site 0400)
    Montreal, Quebec H4A 3J1, Canada
  • Hospital Regional de Concepcion ( Site 0505)
    Concepción, Biobio 4070038, Chile
  • Hospital San Juan de Dios de La Serena ( Site 0500)
    La Serena, Coquimbo Region 1710216, Chile
  • Clinical Research Chile SpA ( Site 0506)
    Valdivia, Los Ríos Region 5110683, Chile
  • Enroll SpA ( Site 0508)
    Santiago, Region M. de Santiago 7500587, Chile
  • Pontificia Universidad Catolica de Chile ( Site 0501)
    Santiago, Region M. de Santiago 8330077, Chile
  • Centro de Investigaciones Clinicas Vina del Mar ( Site 0502)
    Viña del Mar, Valparaiso 2540488, Chile
  • Beijing YouAn Hospital, Capital Medical University ( Site 0605)
    Beijing, Beijing Municipality 100069, China
  • Chongqing Three Gorges Central Hospital ( Site 0618)
    Wanzhou District, Chongqing Municipality 404100, China
  • The First People's Hospital of Foshan-Infection Department ( Site 0612)
    Foshan, Guangdong 528041, China
  • General Hospital of Ningxia Medical University ( Site 0607)
    Yinchuan, Ningxia 750004, China
  • Xinhua Hospital Affiliated to Jiaotong University School of Medicine ( Site 0602)
    Shanghai, Shanghai Municipality 200092, China
  • The Affiliated Hospital of Hangzhou Normal University ( Site 0600)
    Hangzhou, Zhejiang 310015, China
  • Fundacion Santa Fe de Bogota ( Site 0705)
    Bogotá, Bogota D.C. 110111, Colombia
  • CHU de Nice Hopital de l Archet II ( Site 0800)
    Nice, Alpes-Maritimes 06202, France
  • hopital haut leveque chu de bordeaux-Service d'Hépato-gastroentérologie ( Site 0805)
    Pessac, Aquitaine 33600, France
  • Hopital de la Croix-Rousse ( Site 0809)
    Lyon, Auvergne 69004, France
  • CHU Dijon Bourgogne - Hopital F. Mitterrand ( Site 0816)
    Dijon, Bourgogne-Franche-Comté 21079, France
  • CHU Besançon ( Site 0806)
    Besançon, Franche-Comte 25000, France
  • Centre Hospitalier et Universitaire Dupuytren ( Site 0810)
    Limoges, Haute-Vienne 87042, France
  • Hôpital Beaujon ( Site 0804)
    Clichy, Hauts-de-Seine 92110, France
  • C.H.U. Nancy Hopital de Brabois ( Site 0803)
    Vandœuvre-lès-Nancy, Meurthe-et-Moselle 54500, France
  • Hôpital Claude Huriez ( Site 0811)
    Lille, Nord 59037, France
  • Hopital Henri Mondor ( Site 0808)
    Créteil, Val-de-Marne 94000, France
  • A.P.H. Paris, Hopital Saint Antoine ( Site 0807)
    Paris, 75012, France
  • Hopital de la Pitie Salpetriere ( Site 0813)
    Paris, 75013, France
  • Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 0812)
    Paris, 75679, France
  • Universitaetsklinikum Freiburg ( Site 0446)
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Universitätsklinikum Frankfurt-Medizinische Klinik 1 ( Site 0445)
    Frankfurt am Main, Hesse 60590, Germany
  • Johannes Gutenberg Universitat Mainz ( Site 0442)
    Mainz, Rhineland-Palatinate 55131, Germany
  • Universitaetsklinikum Leipzig ( Site 0447)
    Leipzig, Saxony 04103, Germany
  • Charite Universitaetsmedizin Berlin ( Site 0443)
    Berlin, 13353, Germany
  • Hippokration University Hopsital-4th Department of Internal Medicine ( Site 3300)
    Thessaloniki, Central Macedonia 5 46 42, Greece
  • Queen Mary Hospital ( Site 1003)
    Hong Kong, 000000, Hong Kong
  • Prince of Wales Hospital ( Site 1001)
    Shatin, Hong Kong
  • Prince of Wales Hospital ( Site 1002)
    Shatin, Hong Kong
  • Rambam Medical Center ( Site 1201)
    Haifa, 3109601, Israel
  • Carmel Medical Center ( Site 1203)
    Haifa, 3436212, Israel

Showing the first 100 of 180 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Raji A, Gantz I, Crutchlow M, Flynn H, Xu L, Rodgers AJ, Krishnan R, Rizk ML, Hu S, Kaufman KD, Engel SS; MK-3655 P001 Study Group. Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-Cirrhotic MASH. Aliment Pharmacol Ther. 2025 Apr;61(7):1152-1162. doi: 10.1111/apt.70038. Epub 2025 Feb 21. PubMed 39984821 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Apr 2023, 29 months.

Results were first posted in Apr 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2020
First posted
Oct 12, 2020
StartActual
Nov 11, 2020
Primary completionActual
Apr 13, 2023
CompletionActual
Apr 13, 2023
Results first posted
Apr 29, 2024
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04583423
Responsible party
Sponsor
First posted
Oct 12, 2020
Start date
Nov 11, 2020
Primary completion
Apr 13, 2023
Completion
Apr 13, 2023
Results posted
Apr 29, 2024
Last update
Jul 17, 2025

Study contacts

Medical Director, MD
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion